{
    "clinical_study": {
        "@rank": "1337", 
        "acronym": "Ustekinumab", 
        "arm_group": [
            {
                "arm_group_label": "Ustekinumab", 
                "arm_group_type": "Experimental", 
                "description": "Ustekinumab, Tacrolimus and Sirolimus"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Tacrolimus, and Sirolimus"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine whether treatment with ustekinumab will alter the ratio of Treg/total CD4+\n      cells in peripheral blood at day 30 post-hematopoietic cell transplantation (HCT)."
        }, 
        "brief_title": "Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Graft vs. Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "detailed_description": {
            "textblock": "This is a comparative study to assess the biologic and clinical activity of the agent\n      ustekinumab when given in concert with our established regimen of SIR/TAC. Patients will be\n      randomly assigned between the standard regimen of tacrolimus/sirolimus (TAC/SIR + placebo)\n      vs. the investigational regimen of tacrolimus/sirolimus/ustekinumab (TAC/SIR/U) in a 1:1\n      scheme."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hematologic disorder requiring allogeneic hematopoietic cell transplantation\n\n          -  Adequate vital organ function:\n\n          -  Left ventricular ejection fraction (LVEF) >/= 45% by MUGA scan\n\n          -  FEV1, FVC, and diffusing lung capacity oxygenation (DLCO) >/= 50% of predicted values\n             on pulmonary function tests\n\n          -  Transaminases (AST, ALT) < 3 times upper limit of normal values\n\n          -  Creatinine clearance >/= 50 cc/min.\n\n          -  Performance status:  Karnofsky Performance Status Score >/= 60%.\n\n        Exclusion Criteria:\n\n          -  Active infection not controlled with appropriate antimicrobial therapy\n\n          -  HIV, hepatitis B, or hepatitis C infection\n\n          -  Sorror's co-morbidity factors with total score > 3\n\n          -  Important modification to co-morbidity index calculation: DLCO will not be included\n             in assessment of pulmonary risk, excepting those with DLCO < 50%, who will merit a\n             score of 3 and thereby be excluded from the trial.\n\n          -  Anti-thymocyte globulin (ATG) as part of the conditioning regimen\n\n          -  Cyclophosphamide as part of the conditioning regimens"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713400", 
            "org_study_id": "MCC-16743"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ustekinumab", 
                "description": "One subcutaneous injection will be administered on day -1 and repeated on day +20 after transplant", 
                "intervention_name": "Ustekinumab", 
                "intervention_type": "Drug", 
                "other_name": "STELARA"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) will be administered via the identical route and schedule as ustekinumab.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus", 
                "Tacrolimus", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute Graft vs. Host Disease (aGVHD)", 
            "Graft vs. Host Disease (GVHD)"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "H. Lee Moffitt Cancer Center & Research Institute", 
            "url": "http://www.moffitt.org/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H Lee Moffitt Cancer Center & Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Joseph Pidala, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treg/total CD4+ ratio at day 30 following HCT", 
            "measure": "Treg/total CD4+ ratio", 
            "safety_issue": "No", 
            "time_frame": "30 days post transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713400"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Incidence of acute graft vs. host disease will be characterized weekly from day of transplant to day 100 using the 1995 updated grading scheme for GVHD developed by Glucksberg, et al.", 
            "measure": "Incidence of Acute Graft vs. Host Disease", 
            "safety_issue": "No", 
            "time_frame": "100 days post transplant"
        }, 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Gateway for Cancer Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}